Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jacobson Pharma, a Hong Kong Generic Drugmaker, Stages $85 Million IPO

publication date: Sep 21, 2016
Jacobson Pharma, Hong Kong's largest generic drug maker, completed an $85 million IPO on the Hong Kong exchange. Eight of Jacobson's nine production facilities and almost all of its sales are in Hong Kong. According to the company, it has a 30% share of Hong Kong generic drug revenues, more than the next two companies combined. Jacobson makes generic drugs and TCM products, which it sells to public hospitals and private clinics and pharmacies. The company says it will allocate 45% of the proceeds to strategic acquisitions. More details....

Stock Symbol: (HK: 2633)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital